Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

Abstract

Significantly greater treatment adherence was observed for subcutaneous administration of denosumab every 6 months than for oral alendronate once weekly.

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

“…This has been recently confirmed by an open-label study of 250 osteoporotic women who were randomized to either denosumab or branded oral alendronate. [64] In the first 12 months, significantly more patients who received denosumab than alendronate were treatment persistent (risk ratio for discontinua-tion 0.54; p = 0.049). [64] Patients receiving denosumab were therefore assumed in our model to have a 46% lower risk of treatment discontinuation than patients receiving oral bisphosphonates.…”

“…[64] In the first 12 months, significantly more patients who received denosumab than alendronate were treatment persistent (risk ratio for discontinua-tion 0.54; p = 0.049). [64] Patients receiving denosumab were therefore assumed in our model to have a 46% lower risk of treatment discontinuation than patients receiving oral bisphosphonates. Therefore, 22.9%, 9.8%, 4.5%, 3.0% and 2.2% of patients treated with denosumab were assumed to discontinue therapy at 6 months, 1 year, 1.5 years, 2 years and 2.5 years, respectively.…”

Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

“…Adherence with alendronate in our study was good, with around 80% of patients achieving adequate adherence. Adherence of this level is commonly observed in clinical trials, likely due to patients in clinical trials being motivated and receiving regular reminders from the investigators to take their medication [25][26][27]. However, compliance with therapy for osteoporosis in clinical practice, as with other chronic disorders, is often low [4,7].…”

Current and future treatment options in osteoporosis

“…Since the publication of this study, suspected cases of ONJ have been described in patients on denosumab [61,62] but to date these case reports remain very limited. Significantly greater treatment adherence was observed for subcutaneous administration of denosumab every 6 months than for oral alendronate once weekly [63] with a risk ratio for non-adherence at 12 months of 0.58 (p = 0.043) for denosumab compared with alendronate.…”